DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q2 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18).

For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.